Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience

Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients fr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical transplantation 2022-05, Vol.36 (5), p.e14591-n/a
Main Authors: Chen, Qiudong, Singer‐Englar, Tahli, Kobashigawa, Jon A., Roach, Amy, Emerson, Dominic, Megna, Dominick, Ramzy, Danny, Catarino, Pedro, Patel, Jignesh K., Kittleson, Michelle, Czer, Lawrence, Chikwe, Joanna, Esmailian, Fardad
Format: Article
Language:English
Subjects:
Allografts
heart (allograft) function/dysfunction
heart disease
Heart Diseases
Heart Transplantation - adverse effects
Humans
organ perfusion and preservation
Organ Preservation
patient survival
Perfusion
Tissue Donors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections. Results Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p > .5). Conclusions In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.
ISSN:0902-0063
1399-0012
DOI:10.1111/ctr.14591